Effects of topical isoxsuprine ointment on imiquimod-induced psoriasiform skin inflammation in mice
Open Access
- 8 August 2024
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (2) , 1545-1556
Abstract
This study assesses the potential positive impact of a 0.05% isoxsuprine ointment on psoriasiform skin inflammation generated by imiquimod in mouse models. Thirty-two male albino mice were allocated into four groups: the control group (which received topical emollients twice daily for 16 days), the induction group (which received imiquimod cream (5%) for 8 days, twice daily followed by petrolatum gel (15%) for another 8 days), and the other two groups, which received imiquimod cream (5%) for 8 days followed by either clobetasol ointment (0.05%) or isoxsuprine ointment (0.05%) twice daily for an additional 8 days. At the end of the experiment, mice were sacrificed by ethical standards, and levels of TNF-α, IL-6, IL-17A, IL-23, and VEGF were measured; PASI and Backer’s score were examined, in addition to the histopathology of skin tissue. Each clobetasol and isoxsuprine group displayed a significant reduction in tissue homogenate levels of TNF-α, IL-6, IL-17A, IL-23, and VEGF, besides increments in IL-10 compared to the induction group. Some markers (IL-17A, IL23, and VEGF) showed no significant difference between clobetasol and the isoxsuprine group. In contrast, the other markers (TNF-α, IL6, and IL10) showed significant differences between clobetasol and isoxsuprine groups. Isoxsuprine ointment showed comparable efficacy to clobetasol ointment in treating imiquimod-induced psoriasiform skin inflammation in mice models, probably due to its possible effect of anti-inflammatory and immunomodulatory activities.Keywords
This publication has 63 references indexed in Scilit:
- The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm StudyDermatology and Therapy, 2021
- Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated ComorbiditiesDermatology and Therapy, 2021
- Multi-component clobetasol-loaded monolithic lipid-polymer hybrid nanoparticles ameliorate imiquimod-induced psoriasis-like skin inflammation in Swiss albino miceActa Biomaterialia, 2020
- Anabolic and lipolytic actions of beta2‐agonists in humans and antidoping challengesDrug Testing and Analysis, 2020
- Psoriasis2019
- Unmet Needs in the Field of Psoriasis: Pathogenesis and TreatmentClinical Reviews in Allergy & Immunology, 2017
- Beta‐Adrenoceptor Activation Reduces Both Dermal Microvascular Endothelial Cell Migration via a cAMP‐Dependent Mechanism and Wound AngiogenesisJournal of Cellular Physiology, 2014
- Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stressArchives of Dermatological Research, 2012
- Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokinesCurrent Rheumatology Reports, 2007